Zinzino AB AI Stock Analysis
Want to see SE:ZZ.B full AI Analyst Report?
Zinzino AB (ZZ.B) AI Stock Analysis
Zinzino AB
(Nasdaq OMX AB:ZZ.B)
The company's financial health is a major strength, with explosive growth, a fortress balance sheet, and excellent cash flow. This is significantly offset by extremely weak technicals, as the stock is in a clear downtrend and deeply oversold. The attractive valuation, featuring a low P/E and high dividend yield, provides a partial counterbalance, but the current market momentum is a substantial headwind.
Zinzino AB (ZZ.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 387.06M
- Dividend Yield
- 5.06%
- Average Volume (3M)
- 75.35K
- Price to Earnings (P/E)
- 9.9
- Beta (1Y)
- 0.74
- Revenue Growth
- 26.78%
- EPS Growth
- 74.48%
- Country
- Sweden
- Employees
- 370
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
Zinzino AB Business Overview & Revenue Model
Company Description
Operating as a direct sales enterprise, Zinzino AB (publ) markets and distributes a comprehensive selection of nutritional supplements, coffee products, coffee machines, and associated accessories. The company's diverse offerings encompass health-foc...
How the Company Makes Money
Zinzino makes money primarily by selling its health and wellness products to end customers through a direct-sales (network marketing) model. Revenue is generated from: (1) Product sales: the core of revenue comes from selling nutritional supplements...
Zinzino AB Financial Statement Overview
Summary
Financial performance is exceptional, driven by explosive revenue growth, a pristine balance sheet with negligible debt, and robust cash flow generation with near-perfect conversion. Returns on equity are consistently high, indicating efficient capital use.
Income Statement
78PositiveBalance Sheet
85Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.63B | 3.17B | 2.21B | 1.76B | 1.36B | 1.29B |
| Gross Profit | 1.09B | 272.48M | 732.48M | 645.93M | 378.45M | 345.39M |
| EBITDA | 531.50M | 305.82M | 253.59M | 245.88M | 117.02M | 137.95M |
| Net Income | 423.29M | 324.32M | 169.17M | 163.74M | 67.70M | 86.20M |
Balance Sheet | ||||||
| Total Assets | 2.23B | 1.75B | 1.21B | 842.13M | 651.25M | 605.21M |
| Cash, Cash Equivalents and Short-Term Investments | 841.99M | 771.00M | 463.05M | 321.24M | 161.88M | 235.73M |
| Total Debt | 62.22M | 41.99M | 46.06M | 61.38M | 49.58M | 38.94M |
| Total Liabilities | 1.15B | 1.05B | 818.94M | 578.34M | 490.88M | 453.49M |
| Stockholders Equity | 1.08B | 707.20M | 386.14M | 259.97M | 154.45M | 143.05M |
Cash Flow | ||||||
| Free Cash Flow | 681.34M | 529.96M | 295.19M | 234.36M | 17.92M | 143.82M |
| Operating Cash Flow | 688.13M | 541.87M | 309.11M | 246.14M | 42.86M | 153.49M |
| Investing Cash Flow | -14.75M | -91.91M | -98.67M | -11.92M | -35.42M | -11.98M |
| Financing Cash Flow | -241.13M | -113.12M | -68.63M | -74.87M | -81.28M | -49.00M |
Zinzino AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ZZ.B, the sentiment is Negative. The current price of 118.50 is below the 20-day moving average (MA) of 126.05, below the 50-day MA of 131.68, and below the 200-day MA of 133.43, indicating a bearish trend. The MACD of -5.89 indicates Positive momentum. The RSI at 39.01 is Neutral, neither overbought nor oversold. The STOCH value of 26.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ZZ.B.
Zinzino AB Peers Comparison
Overall Rating
SE:CLA.B74Outperform
SE:ZZ.B68Neutral
SE:MSON.B67Neutral
SE:SECARE60.3Neutral
SE:HUMBLE52Neutral
SE:NNH51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | SEK 18.00B | 19.48 | 15.30% | 2.25% | 0.98% | 26.84% | |
| 68Neutral | SEK 4.67B | 9.86 | 48.04% | 5.06% | 26.78% | 74.48% | |
| 67Neutral | SEK 1.38B | 8.31 | 5.43% | 2.32% | -1.42% | ― | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 60Neutral | SEK 3.20B | 37.87 | 1.24% | 1.37% | 2.73% | 36.67% | |
| 52Neutral | SEK 2.75B | -6.02 | -9.80% | ― | 3.05% | -1130.58% | |
| 51Neutral | SEK 96.03M | 20.95 | ― | 1.61% | 2.70% | -43.94% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ZZ.B | Zinzino AB Class B | 118.50 | -38.29 | -24.42% | |
| SE:CLA.B | Cloetta AB Class B | 62.35 | 27.22 | 77.47% | |
| SE:MSON.B | Midsona AB Class B | 9.48 | 1.01 | 11.92% | |
| SE:SECARE | Swedencare AB | 20.45 | -15.47 | -43.07% | |
| SE:HUMBLE | Humble Group AB | 6.18 | -1.28 | -17.16% | |
| SE:NNH | New Nordic Healthbrands AB | 15.50 | -6.34 | -29.04% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
